Strategic collaboration creates a seamless US-APAC manufacturing corridor, enabling local production for global clinical trials and enhancing patient access to next-generation medicines. April 21, 2026 -- Andelyn Biosciences, ("Andelyn") a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization ("CDMO"), and ENCell Co., Ltd. ("ENCell"), a Korea-based advanced biopharmaceutical CDMO, announced today the signing of a Collaboration Agreement to establi

April 21, 2026 -- Circulating white blood cells called neutrophils are some of the immune system's first responders. Their numbers shoot up during infection and inflammation, shifting the ratio of neutrophils to other types of immune cells in the blood. This ratio, called the neutrophil to lymphocyte ratio (NLR), is easily obtained from a complete blood cell count, which is used by clinicians to diagnose infection and other immune conditions. Now, a new study led by researchers at NYU Langone

Data demonstrate potent multi-target activity, high specificity, and a novel approach to overcoming fundamental limitations of T cell engagers in solid tumors April 20, 2026 -- Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, today presented new preclinical data for its lead program, DBXO-1, at the American Association for Cancer Research (AACR) Annual Meeting 2026, which is being held April 17–22 in San Diego, California. The data were included

AstraZeneca announced Tuesday that a Phase III study of Ultomiris (ravulizumab) in adults with IgA nephropathy (IgAN) met its primary endpoint, setting up marketing applications for the long-acting C5 complement inhibitor in this indication. "These positive data demonstrate that C5 complement inhibition with Ultomiris results in a rapid and clinically meaningful reduction in proteinuria as early as week 10 and underscores its potential as a disease-modifying approach in IgAN," said Marc Dunoyer

ADCE-T02, a potential best-in-class Tissue Factor targeted antibody-drug conjugate (ADC), enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors Two ADCE-T02 publications highlighting important preclinical results at the 2026 AACR Annual Meeting ADCE-D01, a first-in-class uPARAP targeted ADC, granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) First patient dosed in Phase I trial of ADCE-B05, an ADC directed against an undisclosed first-in-cla

April 21, 2026 -- Ionetix Corporation ("Ionetix"), a leading particle accelerator company focused on the medical, materials testing and nuclear energy space announced today it raised more than $30 million in a private placement offering at $3.00 per share. In addition, the company completed a go-public reverse merger transaction with JDEV Acquisition Corp., which has been renamed Ionetix Corp. Ionetix's patent-protected superconducting cyclotron technology supports unique particle accelerator s

Seven abstracts accepted for presentation include data from long-term follow-up studies and a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA® (infliximab-dyyb) Findings emphasize clinical decision-making in long-term management of inflammatory bowel disease (IBD), reinforcing Celltrion's commitment to elevating the standard of care and addressing unmet medical need in gastroenterology April 21, 2026 -- Celltrion, Inc. today announced that seven abstrac

Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial Building on the existing indication in cisplatin-ineligible muscle-invasive bladder cancer (MIBC), if approved, this regimen would be the first and only perioperative treatment for patients with MIBC regardless of cisplatin eligibility, marking a potential new standard of care April 20, 2026 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer

April 20, 2026 -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has completed its acquisition of CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The acquisition follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio® System where it is commercially available in the U.S., Europe and Japan. The acquisition is valued at $585 million

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner Advancing felzartamab – a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions – in the Greater China Region presents an important opportunity in a key global market Agreement builds on TJ Biopharma's development success of felzartamab in China and productive clinical collaboration in Biog